OCUL

Ocular Therapeutix, Inc.distress 2/10 · well-funded / low risk

$8.45-2%today-48% from 52w high

ocutx.com325 employeesFounded 2006Bedford, MABiotechnology

Ophthalmology 1

Lead: wet age-related macular degeneration · target VEGF · est. market ~$12B (approx, global)

Revenue

$11M

Liquidity

$667M

Runway

3.0 yrs

Shares 1y

+26%

Price & events

-24.0% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.6%

-7.8%

-16.5%

-11.9%

-17.7%

-29.3%

+5.0%

-31.6%

-57.6%

All

Overview

Market Cap: $1.85B
Volume: 121.19K
52 Week Range: $6.88 – $16.11
Total Shares: 218.96M
Float Shares: 184.37M
Short %: 14.40%
% Held by Insiders: 0.94%
% Held by Institutions: 95.72%
RVOL: 0.04x
Beta: 0.88

Pipeline stages · 3 programs

OTX-TKI

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-01-08

Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injec

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-03

OTX-TKI (axitinib implant), AfliberceptVEGF

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 4 trials · 3 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2027-01-08 Estimated 50% readout ~2027-03-24	Phase 3	OTX-TKI, Aflibercept	Neovascular Age-related Macular Degeneration	—	active not recruiting
2027-03 Estimated 50% readout ~2027-05-15	Phase 3	Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injec	Non-Proliferative Diabetic Retinopathy	—	recruiting
2030-08-01 Estimated 50% readout ~2030-10-15	Phase 3	OTX-TKI	Neovascular Age-Related Macular Degeneration (nAMD)	—	recruiting
2026-04-29	Phase 3	OTX-TKI (axitinib implant), Aflibercept	Neovascular Age-Related Macular Degeneration	344	active not recruiting